Global Extractable and Leachable Testing Services Market Revenue Grows at a CAGR of 14.97%

Introduction

Straits Research released its highly anticipated report, “Global Extractable and Leachable Testing Services Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 1.14 billion in 2025 and is anticipated to grow to USD 4.00 billion by 2034, growing at a CAGR of 14.97% from 2026-2034.

Market Dynamics

The growth of the extractables and leachable testing services market is primarily driven by the increasing complexity of pharmaceutical formulations and the expansion of biologics and combination drug-device products that demand advanced analytical validation. As biologics, vaccines, and cell-based therapies rely on sensitive packaging systems, pharmaceutical companies are placing greater emphasis on material compatibility studies to prevent chemical contamination and ensure long-term product stability. Regulatory agencies such as the U.S. FDA, EMA, and USP have reinforced the need for comprehensive extractables and leachable assessments across the product lifecycle, which has encouraged manufacturers to outsource these technically demanding studies to specialized laboratories equipped with mass spectrometry and chromatographic platforms. However, the market faces a restraint due to the high cost and extended timelines associated with method development, toxicological risk evaluation, and validation protocols. Smaller laboratories often struggle with the financial and technical barriers of maintaining advanced instrumentation and meeting varied international compliance standards, which can slow service accessibility and market expansion. Despite these challenges, a substantial opportunity lies in the widening application of E&L testing within emerging sectors such as nutraceuticals, regenerative medicine, and medical packaging innovation. As global healthcare systems evolve toward safer and more regulated product environments, the scope for E&L testing is expanding beyond traditional pharmaceuticals, presenting new avenues for contract testing organizations to diversify their analytical portfolios and strengthen partnerships with packaging manufacturers and bioprocessing companies.

Market Highlights

• Product Type: Based on Product Type, the container closure systems segment dominated the market in 2025, accounting for 34.71% of share in 2025.
• Application: Based on Application, the orally inhaled and nasal drug products segment dominated the market in 2025 with a revenue share of 44.23%.
• Regional Insights: North America dominated the market with more than 47% of market share in 2025, driven by the strong presence of established analytical laboratories, stringent regulatory oversight from the U.S. FDA and Health Canada, and growing demand for packaging safety evaluations in biologics and medical device manufacturing.

Competitive Players

1. Pace
2. Smithers 
3. Auriga Research Private Limited
4. SCHOTT Pharma AG & Co. KGaA 
5. Analytica Chemie
6. Gateway Analytical
7. Reading Scientific Services Ltd 
8. Eurofins Scientific
9. Intertek Group plc
10. SGS Société Générale de Surveillance SA
11. WuXi AppTec
12. Merck KGaA
13. West Pharmaceutical Services, Inc.
14. Pacific Biolabs
15. BA Sciences
16. Sotera Health Academy
17. Charles River Laboratories
18. Labcorp
19. Others

Recent Developments

October 2024: Recipharm AB announced that it had expanded its pharmaceutical‐development capabilities through strategic investments and the integration of advanced technologies. The company aimed to offer services for early- and late-stage product development, including clinical-trial supply and commercial technologies.

Segmentation

1. By Product Type (2026-2034)
   1. Container Closure Systems
   2. Single-use Systems
   3. Drug Delivery Systems
   4. Others
2. By Application (2026-2034)
   1. Parenteral Drug Products
   2. Orally Inhaled and Nasal Drug Products
   3. Ophthalmic